Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Roger Brüggemann

Roger Brüggemann

Researcher
 
 
  • Comment on

    • nov. 2022
    • Beatrijs, Mertens, et al
    • Journal of Antimicrobial Chemotherapy
  • Liposomal amphotericin B-the past

    • nov. 2022
    • R. J., Brüggemann, et al
    • Journal of Antimicrobial Chemotherapy
  • Risk-proportionate approach to paediatric clinical trials

    • okt. 2022
    • Mandy, Wan, et al
    • Clinical Trials
  • Tackling the emerging threat of antifungal resistance to human health

    • sep. 2022
    • Matthew C., Fisher, et al
    • Nature Reviews Microbiology
  • Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults

    • aug. 2022
    • Lu, Chen, et al
    • Journal of Antimicrobial Chemotherapy
View all publications